Table 1

Baseline Clinical Characteristics of Study Patientslegend legend

Metoprolol (n = 26)Carvedilol Group (n = 25)p Value
Age (years)60.4 (2.3)58.7 (3.0)0.65
Range35–8033–86
Gender
Male2317
Female38
Etiology
IDC1013
ICM56
HTHD116
NYHA functional class
II710
III1914
IV01
Mean NYHA class2.7 (0.09)2.6 (0.11)0.53
Symptom questionnaire score13.1 (1.8)17.2 (3.0)0.23
ETT (6-min walk, feet)1164 (46)1122 (51)0.55
Baseline blood pressure (mm Hg)
Sitting126(3)/75(3)130(5)/78(3)0.51/0.51
Standing127(3)/78(3)130(5)/83(3)0.54/0.28
Heart rate (beats/min)84.8 (2.5)82.8 (2.7)0.60
LVEF (%)25.5 (1.8)26.4 (1.8)0.72
LVEDD (cm)6.8 (0.2)6.7 (0.2)0.93
FS (%)13.8 (1.0)13.7 (0.7)0.88
Treatment
Frusemide2424
Frusemide mean dose (mg)49 (7.0)58 (8)
ACEI/AIIRA2524
Nitrates1616
  • legend Values are mean ± SEM.

  • legend ACEI = angiotensin-converting enzyme inhibitor; AIIRA = angiotensin II receptor antagonist; ETT = exercise tolerance test; FS = LV fractional shortening; HD = heart disease; HTHD = hypertensive heart disease; ICM = ischemic cardiomyopathy; IDC = idiopathic dilated cardiomyopathy; LVedd = LV end diastolic dimension; LVEF = LV ejection fraction (gated blood pool scan).